IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma.
Mutations in isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2) occur in most grade 2 and 3 gliomas, secondary glioblastomas, and a subset of acute myelogenous leukemias but have not been detected in other tumor types. The mutations occur at specific arginine residues and result in the acquisition of a novel enzymatic activity that converts 2-oxoglutarate to D-2-hydroxyglutarate. This study reports IDH1 and IDH2 genotyping results from a set of lymphomas, which included a large set of peripheral T-cell lymphomas. IDH2 mutations were identified in approximately 20% of angioimmunoblastic T-cell lymphomas (AITLs), but not in other peripheral T-cell lymphoma entities. These results were confirmed in an independent set of AITL patients, where the IDH2 mutation rate was approximately 45%. This is the second common genetic lesion identified in AITL after TET2 and extends the number of neoplastic diseases where IDH1 and IDH2 mutations may play a role.
Campbell Family Institute for Breast Cancer Research at Princess Margaret Hospital, University Health Network, Toronto, ON, Canada.
Rob A
RA
Cairns
Javeed
J
Iqbal
François
F
Lemonnier
Can
C
Kucuk
Laurence
L
de Leval
Jean-Philippe
JP
Jais
Marie
M
Parrens
Antoine
A
Martin
Luc
L
Xerri
Pierre
P
Brousset
Li Chong
LC
Chan
Wing-Chung
WC
Chan
Philippe
P
Gaulard
Tak W
TW
Mak
D000368:Aged; D005260:Female; D005787:Gene Frequency; D005838:Genotype; D006801:Humans; D007119:Immunoblastic Lymphadenopathy / Q000201:enzymology / Q000235:genetics* / Q000473:pathology; D007521:Isocitrate Dehydrogenase / Q000235:genetics*; D053208:Kaplan-Meier Estimate; D016399:Lymphoma, T-Cell / Q000201:enzymology / Q000235:genetics* / Q000473:pathology; D016411:Lymphoma, T-Cell, Peripheral / Q000201:enzymology / Q000235:genetics / Q000473:pathology; D008297:Male; D009154:Mutation; D059645:Mutation Rate; D011379:Prognosis
C538784:IDH2 protein, human; D007521:Isocitrate Dehydrogenase; C543588:IDH1 protein, human